Abstract

Abstract:

Background. Little is known about real-world outcomes for new interferon-free treatment for hepatitis C virus (HCV) among underserved and diverse communities. Objective. To identify predictors of treatment prescription and evaluate outcomes as measured by sustained virologic response (SVR) with HCV RNA testing three months after therapy completion. Design. Retrospective cohort at a safety-net health care system. Participants. Patients with (1) at least one clinical visit between December 6, 2013, and December 31st 2014; and (2) at least three months follow-up. Key results. Predominantly non-White cohort (61%). Of 1,284 HCV-infected patients 121 prescribed sofosbuvir-based therapy. Severe liver fibrosis (OR 1.66, 95% CI 1.05, 2.64) independently associated with treatment prescription. In those with evaluable HCV RNA, SVR was 99%. Conclusion. Cure rates similar to clinical trial data can be achieved in diverse underserved communities.

pdf

Additional Information

ISSN
1548-6869
Print ISSN
1049-2089
Pages
pp. 1333-1344
Launched on MUSE
2017-11-21
Open Access
No
Back To Top

This website uses cookies to ensure you get the best experience on our website. Without cookies your experience may not be seamless.